Phathom Pharmaceuticals, Inc.
6.22USD
-0.0600 (-0.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PHAT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.11▼ | $0.19 | 0 | 3 |
| Next quarter | $0.01▼ | $0.16 | 0 | 2 |
| Current year | -$0.04▼ | -$0.04 | 0 | 1 |
| Next year | $0.96▼ | $1.43 | 0 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-09-30 | $0.03 | $0.04 | +0.01 (+39.9%) |
| 2026-06-30 | -$0.1 | $0 | +0.10 (+100.0%) |
| 2026-03-31 | -$0.19 | -$0.18 | +0.01 (+7.3%) |
| 2025-12-31 | -$0.19 | -$0.08 | +0.11 (+57.4%) |
101 ratings from 11 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Leerink Partners | Initiated | Market Perform | $10 | Sep 9, 2026 |
| Barclays | Maintained | Overweight | $18 $14 | Aug 17, 2026 |
| Guggenheim | Maintained | Buy | $25 $22 | Jul 31, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $26 | Jul 31, 2026 |
| Needham | Maintained | Buy | $28 $22 | Jul 30, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $26 | Jun 17, 2026 |
| Barclays | Upgraded from Equal-Weight | Overweight | $16 $18 | Mar 27, 2026 |
| Guggenheim | Maintained | Buy | $20 $25 | Feb 27, 2026 |
| Barclays | Initiated | Equal-Weight | $16 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20 $26 | Oct 31, 2025 |
| Craig-Hallum | Maintained | Buy | $12 $17 | Jun 9, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Jun 9, 2025 |
| Needham | Maintained | Buy | $28 | Jun 6, 2025 |
| Goldman Sachs | Maintained | Neutral | $10 $5 | May 2, 2025 |
| Guggenheim | Maintained | Buy | $18 $12 | May 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $28 $20 | May 2, 2025 |
| Craig-Hallum | Maintained | Buy | $19 $12 | May 2, 2025 |
| Needham | Reiterated | Buy | $28 | Apr 21, 2025 |
| Goldman Sachs | Maintained | Neutral | $12 $10 | Apr 17, 2025 |
| Needham | Reiterated | Buy | $28 | Apr 9, 2025 |
| Guggenheim | Reiterated | Buy | — | Apr 2, 2025 |
| Needham | Reiterated | Buy | $28 | Apr 2, 2025 |
| Goldman Sachs | Maintained | Neutral | $18 $12 | Mar 10, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $28 | Mar 7, 2025 |
| Needham | Reiterated | Buy | $28 | Mar 6, 2025 |
49 filings from 14 insiders · 0 buy / 0 sell over 6m
Officers and directors of PHAT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PARIKH ASITDirector | Gift | 28.0k | — | — | May 22, 2026 |
| PARIKH ASITDirector | Exercise | 17.5k | $4.95 | $87k | May 20, 2026 |
| PARIKH ASITDirector | Grant | 24.1k | — | — | May 19, 2026 |
| COLA MICHAEL FDirector | Grant | 24.1k | — | — | May 19, 2026 |
| STENHOUSE MARKDirector | Grant | 24.1k | — | — | May 19, 2026 |
| SCHROEDER THEODORE RDirector | Grant | 24.1k | — | — | May 19, 2026 |
| TOPPER JAMES NDirector and Beneficial Owner of more than 10% of a Class of Security | Grant | 24.1k | — | — | May 19, 2026 |
| KARBE FRANK LDirector | Grant | 24.1k | — | — | May 19, 2026 |
| FIELDS-KUNZ HEIDIDirector | Grant | 24.1k | — | — | May 19, 2026 |
| PARIKH ASITDirector | Gift | 40.0k | — | — | Mar 10, 2026 |
| BREEDLOVE ROBERT CHARLESOfficer | Grant | 15.8k | — | — | Feb 27, 2026 |
| COOK ANNE MARIEOfficer | Grant | 3.5k | — | — | Feb 10, 2026 |
| BASTA STEVEN LChief Executive Officer | Grant | 12.4k | — | — | Feb 10, 2026 |
| PARIKH ASITDirector | Gift | 80.5k | — | — | Jan 23, 2026 |
| PARIKH ASITDirector | Exercise | 8.8k | $10.30 | $90k | Jan 13, 2026 |
| NARULA SANJEEVChief Financial Officer | Grant | 82.7k | — | — | Jan 2, 2026 |
| COOK ANNE MARIEOfficer | Grant | 75.3k | — | — | Jan 2, 2026 |
| BASTA STEVEN LOfficer and Director | Grant | 251.0k | — | — | Jan 2, 2026 |
| PARIKH ASITDirector | Exercise | 8.8k | $10.30 | $90k | Dec 19, 2025 |
| COOK ANNE MARIEOfficer | Grant | 17.4k | — | — | Dec 17, 2025 |
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 8 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 8 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 2 | 8 | 1 | 0 | 0 | Buy1.91 |
| 3 mo ago | 2 | 8 | 1 | 0 | 0 | Buy1.91 |
Members whose judged calls on PHAT have played out most reliably.
No settled calls on PHAT yet. 1 call is open, the first due Oct 29, 2027.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice